Delanzomib [CEP-18770], CAS [[847499-27-8]], Unconjugated

Product Overview

• Article Name: Delanzomib [CEP-18770], CAS [[847499-27-8]], Unconjugated
• Biozol Catalog Number: BSS-BS-75562C
• Supplier Catalog Number: bs-75562C
• Alternative Catalog Number: BSS-BS-75562C-1,BSS-BS-75562C-5
• Manufacturer: Bioss
• Category: Biochemikalien
• Conjugation: Unconjugated

Product Description

Potent, selective, reversible orally bioavailable proteasome inhibitor. Synthetic P2 threonine boronic acid. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.8nM). Cross-reacts and inhibits the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=~70nM). Displays similar potency for the chymotrypsin-like activity of the proteasome compared to bortezomib. Exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors and bone marrow-derived stromal cells relative to bortezomib (Prod. No. bs-75509C). Anticancer compound effective against multiple myeloma in vivo. In vitro, blocks the growth of representative human solid and hematological tumor cell lines (IC50s=5.6-34nM). Shown to down-modulate NF-kappaB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.

Product Properties

• Buffer: Solid
• CAS Number: [847499-27-8]